{"id":"sabin-ipv-bopv-bopv","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability or fussiness"},{"rate":null,"effect":"Mild gastrointestinal symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine combines inactivated poliovirus vaccine (IPV), which contains chemically inactivated poliovirus particles administered by injection, with bivalent oral poliovirus vaccine (bOPV), which contains live attenuated poliovirus types 1 and 3 administered orally. Together, these components induce both systemic and mucosal immunity against poliovirus, providing protection against polio infection and transmission.","oneSentence":"This is a combination polio vaccine containing inactivated poliovirus (IPV) and bivalent oral poliovirus vaccine (bOPV) that stimulates immune responses against poliovirus types to prevent poliomyelitis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:06:29.895Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis (polio) in infants and children"}]},"trialDetails":[{"nctId":"NCT06920069","phase":"PHASE4","title":"Study of Concomitant Administration of the sIPV and DTaP or MMR","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-05-15","conditions":"Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine","enrollment":2640},{"nctId":"NCT05431933","phase":"PHASE3","title":"Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-01-10","conditions":"Poliomyelitis, Vaccine Reaction","enrollment":2001},{"nctId":"NCT06752174","phase":"PHASE3","title":"A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2023-03-08","conditions":"Poliomyelitis","enrollment":300},{"nctId":"NCT03614702","phase":"PHASE3","title":"Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2015-09-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT04232943","phase":"PHASE1","title":"Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2020-01-22","conditions":"Polio","enrollment":87},{"nctId":"NCT04576910","phase":"PHASE4","title":"Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2020-11-05","conditions":"Polio, Vaccine Reaction","enrollment":387},{"nctId":"NCT02521974","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2015-10","conditions":"Adverse Event Following Immunisation","enrollment":164},{"nctId":"NCT03147560","phase":"PHASE4","title":"Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2017-05-02","conditions":"Polio","enrollment":528},{"nctId":"NCT04054492","phase":"PHASE4","title":"To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2018-03-01","conditions":"Vaccination, Reaction - Vaccine","enrollment":604},{"nctId":"NCT03822767","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a \"2+1\"Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-12","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03822754","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-06","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT02477046","phase":"PHASE3","title":"Assessment of Community Transmission of Sabin Type 2 Virus in Bangladesh","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2015-04","conditions":"Vaccine Virus Shedding","enrollment":810},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sabin IPV+ bOPV+ bOPV","genericName":"Sabin IPV+ bOPV+ bOPV","companyName":"Zhejiang Provincial Center for Disease Control and Prevention","companyId":"zhejiang-provincial-center-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"The Sabin IPV+ bOPV+ bOPV vaccine is used to study the prevention of Poliomyelitis, Polio, Diphtheria, Tetanus, and Pertussis, as well as the shedding of vaccine viruses. This vaccine is administered in a \"2+1\" sequential schedule with bOPV in infants, as part of a clinical trial to evaluate its immunogenicity and safety.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}